For years, veterans returning from combat with severe PTSD and addiction have traveled to clinics in Mexico and Central America to try ibogaine, a psychedelic compound that remains illegal in the United States. Among the most vocal advocates for changing that reality has been former Special Forces operator Marcus Capone, co-founder of the Veterans Exploring Treatment Solutions (VETS) nonprofit, who has spoken publicly about his own ibogaine treatment abroad and lobbied Congress to fund domestic research. In April 2026, President Donald J. Trump signed an executive order intended to bring those treatments closer to home. The directive orders the FDA, the Department of Health and Human Services, and the Department of Veterans Affairs to accelerate evaluations of psychedelics as therapies for serious mental illness, and it commits $50 million in federal funds through the Advanced Research Projects Agency for Health (ARPA-H) to match state-level research investments.
What the executive order actually does
The order, titled “Accelerating Medical Treatments for Serious Mental Illness,” contains several concrete directives. It instructs the FDA and the Drug Enforcement Administration to build a pathway allowing eligible patients to access investigational psychedelics under the Right to Try Act, codified as 21 U.S.C. Section 360bbb-0a. That law was originally designed to let terminally ill patients use drugs that have not completed full FDA approval. Applying it to non-terminal psychiatric conditions like PTSD and addiction represents a significant and legally untested expansion of the statute’s reach.
For context, the Right to Try Act became federal law in 2018, but its track record in other drug categories has been modest. A 2023 Government Accountability Office report found that relatively few patients had used the pathway, in part because manufacturers are not required to provide their investigational drugs and because liability and insurance questions remain unresolved. Applying Right to Try to psychedelics introduces additional complications, since the compounds involved carry Schedule I restrictions that add a layer of federal enforcement beyond what most Right to Try applicants have faced.
The order also requires interagency data-sharing agreements so that clinical results held by the VA or HHS reach FDA reviewers faster. And it explicitly ties two existing FDA acceleration tools to psychedelic drug candidates: the Commissioner’s National Priority Voucher (CNPV) pilot program, which can shorten review timelines for designated treatments, and the Breakthrough Therapy Designation program, which expedites development and review of drugs showing substantial improvement over existing options. Neither program is new, but directing them toward psychedelics is.
The $50 million in ARPA-H funds is structured as a match for state investments in psychedelics research. That design connects directly to Texas, where Governor Greg Abbott signed Senate Bill 2308 into law at the Texas Capitol, authorizing state matching funds for ibogaine research targeting neurological and mental health conditions. UTMB Health, working with UTHealth Houston, subsequently received $50 million from the Texas Health and Human Services Commission to lead a two-year multicenter clinical trial focused on addiction, traumatic brain injury, and other behavioral health conditions.
Why ibogaine, and why now
Ibogaine, derived from the root bark of a West African shrub called Tabernanthe iboga, is classified as a federal Schedule I substance, meaning the government considers it to have high abuse potential and no currently accepted medical use. Yet veterans and some members of Congress have promoted it as a treatment for opioid addiction and trauma-related conditions, as the Associated Press has reported. The tension between that advocacy and ibogaine’s legal status is what the executive order attempts to bridge.
The timing also reflects a broader reckoning with psychedelic medicine at the federal level. In August 2024, the FDA rejected the new drug application from Lykos Therapeutics for MDMA-assisted therapy for PTSD, citing concerns about clinical-trial design and data integrity. That rejection stalled what many researchers had considered the most advanced psychedelic therapy in the regulatory pipeline. The executive order can be read, in part, as an attempt to create alternative pathways after that setback, particularly for compounds like ibogaine that have strong veteran-community support but limited formal trial data in the U.S.
It is worth noting that at least one psychedelic compound has already received Breakthrough Therapy Designation from the FDA. In 2018, the agency granted that status to COMP360, a synthetic psilocybin developed by Compass Pathways, for treatment-resistant depression. That precedent shows the FDA is willing to fast-track psychedelics when early clinical evidence is strong enough, but it also underscores how far ibogaine still has to travel through the regulatory process.
What remains uncertain
Several critical details are missing from the public record. The executive order and its accompanying fact sheet do not specify which psychedelic compounds beyond ibogaine qualify for the new Right to Try pathway, nor do they define the patient eligibility criteria that will govern access. The FDA has not released public statements identifying specific psychedelics being considered for Breakthrough Therapy Designation under this initiative.
Implementation timelines are similarly unclear. The order calls for interagency data-sharing memoranda, but no publicly available documents from HHS or the VA detail when those agreements will take effect or what clinical data they will cover. The CNPV pilot program, announced by the FDA in 2025 to shorten review timelines for nationally prioritized treatments, describes its acceleration mechanism in general terms, but the administration has not published a schedule showing when psychedelic-specific applications will enter the queue.
Safety concerns are substantial. Published case reports and observational research have documented serious cardiac risks associated with ibogaine, including dangerous heart-rhythm abnormalities known as QT prolongation. Several deaths have been linked to unsupervised ibogaine use outside clinical settings. The Texas-funded trials at UTMB Health and UTHealth Houston are designed to generate the rigorous safety and efficacy data that regulators need, but those trials operate on a two-year timeline. That means patients may begin seeking access through Right to Try before controlled clinical results are available, since the framework by design permits use of drugs still in the investigational stage.
The interaction between state and federal funding raises its own questions. Texas is currently the only state that has committed large-scale public dollars to psychedelics research at this level. Whether other states will pass similar legislation and qualify for ARPA-H matching funds will determine whether the program has national reach or remains a Texas-centered pilot.
Another gap is how federal agencies will interpret the order’s language around “serious mental illness.” The term can encompass conditions ranging from major depressive disorder and bipolar disorder to schizophrenia and severe PTSD, but it is not defined in the publicly available documents. That ambiguity leaves room for significant variation in which diagnoses qualify for accelerated access and how quickly new indications might be added.
The DEA’s role also remains opaque. The executive order names the agency as a partner in building the new access pathway, but ibogaine’s Schedule I classification means the DEA would need to grant research exemptions or support rescheduling for any large-scale clinical program to function smoothly. No public guidance from the DEA on this question has appeared.
Milestones that will show whether the order delivers
For patients, families, and clinicians, the practical reality is that access to psychedelic treatments is not immediate or guaranteed. The Right to Try pathway still requires that a drug have completed at least a Phase I trial and that a manufacturer is willing to provide it. The FDA’s expedited programs can compress review timelines but do not eliminate the need for robust evidence. And the state-federal matching funds, while substantial, are the opening investment in what will likely be a multi-year process of study, negotiation, and rulemaking.
The most reliable indicators of progress will be concrete milestones: publication of protocol details for the Texas ibogaine trials, any public notices from the FDA about psychedelic applications entering the CNPV queue or receiving Breakthrough Therapy Designation, DEA guidance on research access to Schedule I psychedelics, and formal documents clarifying eligibility and safety monitoring under the new framework.
Until those pieces are visible, the executive order represents a significant policy signal and a real shift in how the federal government talks about psychedelic medicine. But a signed directive is not the same as a functioning clinical program, and the distance between the two will be measured in trial data, regulatory decisions, and the willingness of agencies to move at the pace the White House has demanded.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
